Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04489368
Other study ID # RGCIRC/IRB/80/2020
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 16, 2020
Est. completion date July 2023

Study information

Verified date December 2022
Source Rajiv Gandhi Cancer Institute & Research Center, India
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy (NA-CCRT) followed by surgery is the current standard of care and ample evidence has accumulated supporting the view that complete pathological response (pCR) is a positive prognostic marker for improved outcomes. Predicting the probability of achieving pCR prior to neoadjuvant treatment could permit modification of treatment protocols for those patients unlikely to achieve pCR. Radiomics is a new entrant in the field of imaging where specific features are derived from the intensity and distribution pattern of pixels based on a region-of-interest (ROI). The features thus extracted can then be used for prediction modelling similar to other -omics datasets. Preliminary investigations examining its utility have been performed and its applications have thus far focused on screening and survival prediction after treatment. Due to the multi-dimensional nature of data extracted using radiomics, Artificial Intelligence (AI) methods are ideally suited for analysing and modelling radiomic features. Machine Learning (ML) and Deep Learning (DL)[utilising Convolutional Neural Networks (CNN)] are both part of the AI framework. In contrast to ML, DL is a new entrant and has been utilised by some medical researchers for modelling using prediction-type algorithms. Besides significantly reducing the workflow associated with Radiomics-based research, feature engineering and modelling using DL are immune to the effects of incorrect ROI delineation. However, the main limitation of DL is the 'blackbox' effect, in which the underlying basis of a CNN is not known. This has been mitigated in part by the visualisation of activation maps directly on the image dataset to prove biological plausibility of predictions. The comparative performance of both types of modelling is also not known. Our objective is to investigate pCR probability in our study population using radiomics-based ML and AI-based modelling. We will also investigate the comparative performance of both modelling techniques. For DL based prediction modelling, we will attempt to provide biological plausibility on the basis of activation maps.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 150
Est. completion date July 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ECOG Performance Status: 0-2 - Patients with histopathological or cytopathological confirmed malignancy of the esophagus - Histology: Squamous Cell Carcinoma and Adenocarcinoma - Patients should have received NeoAdjuvant Concurrent Chemoradiation (NACCRT) followed by Surgery - All therapeutic interventions (Radiotherapy, Chemotherapy & Surgery) delivered within participating institutions - At least one pre-NACCRT DICOM imaging dataset (HRCT/ 18-FDG PET-CT/ Radiotherapy planning CT) for each patient Exclusion Criteria: - Patients with any metallic implants in the region of interest - Patient with locally advanced disease or metastatic disease (T4 disease, Fistula, metastases) - Patients with prior history of radiotherapy in the same region - Patients developing a second malignancy in the esophagus

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Neo-Adjuvant Radiotherapy
Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
Drug:
Neo-Adjuvant Chemotherapy
Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
Procedure:
Esophagectomy
Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation

Locations

Country Name City State
Australia Illawarra Cancer Care Centre Wollongong
India Rajiv Gandhi Cancer Institute & Research Center New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Dr Kundan Singh Chufal

Countries where clinical trial is conducted

Australia,  India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Develop models to predict pCR based on pre-neoadjuvant imaging modalities August 2021
Primary Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy January 2020
See also
  Status Clinical Trial Phase
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05406024 - Feasibility Study CORPPS
Terminated NCT02601079 - Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis N/A
Active, not recruiting NCT01745107 - Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Phase 3
Active, not recruiting NCT02969473 - Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT00288119 - Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Terminated NCT01870791 - Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer Phase 2
Active, not recruiting NCT00431756 - Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Not yet recruiting NCT05736705 - Monopolar and Bipolar in Esophageal ESD N/A
Completed NCT02395705 - Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Phase 3
Completed NCT02033213 - Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial N/A
Terminated NCT00653107 - Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only Phase 3
Completed NCT01927016 - Outcomes After Esophageal Cancer Surgery N/A
Completed NCT02558504 - Radiofrequency in the Treatment of Barrett's Oesophagus Phase 4
Active, not recruiting NCT02636088 - Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer Phase 2
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Completed NCT00318903 - Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Phase 2
Recruiting NCT02583087 - ESD for the Treatment of Early Barrett's Neoplasia N/A